Meta Platforms ( NASDAQ:META ) has delivered outstanding performance compared its hyperscaler peers such as Apple ( NASDAQ:AAPL ), Amazon ( NASDAQ:AMZN ), Alphabet ( NASDAQ:GOOG )( NASDAQ:GOOGL ), and Microsoft ( NASDAQ:MSFT ).

ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.

Intel Corporation is in the midst of a massive turnaround, with momentum and improved fundamentals following strategic pivots and leadership changes. INTC's Q4 report is expected to show artificial year-over-year declines, but 2026 guidance points to renewed growth, margin expansion, and business stabilization. Balance sheet and cash flow have notably improved, with debt reduction and positive free cash flow signaling financial health and operational discipline.

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.

Universal Health Services (UHS) possesses solid growth attributes, which could help it handily outperform the market.

Global Payments (GPN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Dentsply Sirona Inc. (XRAY) is the world's largest supplier of dental products and technologies, operating in over 100 countries. XRAY's business is segmented into Connected Technology Solutions, Orthodontic and Implant Solutions, Essential Dental Solutions, and the smaller Wellspect Healthcare. Despite performance issues, its investment grade bonds offering 8.5% current yield remain appealing.

Elon Musk on Friday called Ryanair CEO Michael O'Leary an "utter idiot" who should be fired, escalating a public spat that began after the airline boss ruled out installing Musk's Starlink internet service on Ryanair aircraft.

Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.

IREN's vertically integrated AI cloud targets higher margins, with an 85% EBITDA Microsoft deal, lower power costs and rapidly improving profitability.

IREN Limited's vertically integrated, renewable-powered platform and AI pivot set it apart from HUT 8 amid Bitcoin volatility and rising data-center demand.

Traders believe that the risks of a U.S. strike against Iran persist.

Goldman Sachs Group, Inc. (NYSE: GS) delivered a mixed close to fiscal 2025, with fourth-quarter results weighed down by sizable markdowns and exit costs tied to its consumer platform.

MTN flags one of its weakest early ski seasons in 30+ years, with low snowfall hitting visits and revenues and pushing EBITDA just below guidance.

DOWNERS GROVE, Ill., Jan. 16, 2026 /PRNewswire/ -- Federal Signal Corporation (NYSE: FSS) (the "Company"), a leader in environmental and safety solutions, today announced that it has completed the acquisition of Mega Corp. ("Mega"), a leading manufacturer of specialty vehicles and equipment for use in global metal extraction and construction markets.

Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment.

MARA's Q3 showed momentum beyond Bitcoin mining, with AI inference infrastructure going live and expanded energy partnerships supporting diversification.